FDA approves Protein Sciences' flu vaccine Flublok

01/16/2013 | HealthDay News

Protein Sciences received FDA approval for its new flu vaccine, Flublok, for patients aged 18 to 49. The vaccine "offers the potential for faster startup of the vaccine manufacturing process in the event of a pandemic, because it is not dependent on an egg supply or on availability of the influenza virus," an agency official said. The production method uses recombinant DNA and insect virus expression technology, which have been used in other vaccines.

View Full Article in:

HealthDay News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN